The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Genocea Biosciences's Cash Ratio for the quarter that ended in Mar. 2022 was 1.12.
Genocea Biosciences has a Cash Ratio of 1.12. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Genocea Biosciences's Cash Ratio or its related term are showing as below:
GNCAQ's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.95 * Ranked among companies with meaningful Cash Ratio only.
Genocea Biosciences Cash Ratio Historical Data
The historical data trend for Genocea Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genocea Biosciences's Cash Ratio
For the Biotechnology subindustry, Genocea Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genocea Biosciences's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Genocea Biosciences's Cash Ratio falls into.
Genocea Biosciences Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Genocea Biosciences's Cash Ratio for the fiscal year that ended in Dec. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genocea Biosciences (OTCPK:GNCAQ) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Genocea Biosciences Cash Ratio Related Terms
Thank you for viewing the detailed overview of Genocea Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Genocea Biosciences (Genocea Biosciences) Business Description
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNCAQ has been successfully added to your 